The 15,000 square foot office location is adjacent to their primary production test site, which includes several significant enhancements to operational efficiency, safety, and increased production capabilities.
Commenting on the expansion, Daryl Lamy, President of Nikkiso Cryo, said, “This is an exciting next step for our company and a significant benefit for our customers. NCI will now be able to increase production and reduce turn-around time.”
Nikkiso Cryo’s enhancements also provide benefits for customer remote-site witness testing at the facility, offering significant value and time savings for global customers, particularly beneficial due to Covid-19 travel concerns.